drugset / Trial / NCT06433609
Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Our study is aimed to evaluate the efficacy and safety of novel ADCs named SHR-A1811, SHR-A1921 and SHR-A2102 combined with adebrelimab in HER2-negative advanced breast cancer.
Timeline
- Start
- 2024-08-05
- Primary completion
- 2027-03
- Completion
- 2027-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SHR-A1811 | Monoclonal antibody | — | Intravenous |
| Subject | SHR-A1921 | Monoclonal antibody | — | Intravenous |
| Subject | SHR-A2102 | Other / unclassified | — | Intravenous |
| Background | Adebrelimab | Monoclonal antibody | — | Intravenous |